QuidelOrtho's May 2026 quarterly report said China's volume-based procurement program would not likely have a material impact on total annualized revenue. Third-quarter 2026 results showed China revenue down 45%, and QDEL shares fell roughly 14%.
NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Pricing changes and distributor destocking in China cut QuidelOrtho Corporation (NASDAQ: QDEL) China revenue by 45% in the third quarter of 2026, and QDEL shares fell roughly 14% when the results reached the market. If you bought QDEL and are now holding losses, your losses may be recoverable. Shareholders who lost money are encouraged to submit your QDEL loss details now while the investigation is underway, or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.
China's volume-based procurement program, known as VBP, is a government-run tender system that sets prices for medical products purchased by public hospitals. QuidelOrtho addressed VBP in its Form 10-Q dated May 6, 2026, stating: "Based on current information, we believe that any potential business impact would not likely be material to our total annualized revenue."
About six months later, the third-quarter 2026 report showed China revenue down 45%, with the Company tying the decline to distributor destocking and pricing changes. QDEL shares dropped roughly 14% on the report. SueWallSt notifies investors of a pending investigation into whether QuidelOrtho may not have adequately disclosed risks tied to China's regulatory pricing environment, and whether potential securities law violations occurred.
QDEL shareholders who took losses following the third-quarter 2026 results can request a free evaluation of their QDEL losses today or call (888) SueWallSt.
WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the QDEL Investigation
Q: Who is eligible to participate in the QDEL investigation? A: Investors who purchased QuidelOrtho (NASDAQ: QDEL) stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did QDEL stock drop? A: Shares fell approximately 14% after the Company disclosed third-quarter 2026 results showing a 45% decline in China revenue tied to distributor destocking and pricing changes. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether QuidelOrtho's statements regarding the potential revenue impact of China's volume-based procurement program were materially false or misleading, including its May 6, 2026 statement that any potential business impact "would not likely be material to our total annualized revenue." When the Company disclosed a 45% decline in China revenue in its third-quarter 2026 results, the stock price declined sharply.
Q: What do QDEL investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my QDEL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought QDEL and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/qdel-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-quidelortho-302934828.html
SOURCE SueWallSt.com
